Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AMYT Amryt Pharma (AMYT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Amryt Pharma Stock (NASDAQ:AMYT) 30 days 90 days 365 days Advanced Chart Remove Ads Get Amryt Pharma alerts:Sign Up Key Stats Today's Range$14.63▼$14.7650-Day Range$14.55▼$14.7052-Week Range$6.41▼$14.77Volume2.39 million shsAverage Volume757,360 shsMarket Capitalization$940.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAmryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.Read More… Remove Ads Receive AMYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AMYT Stock News HeadlinesAlembic Pharmaceuticals Ltd.October 13, 2023 | wsj.comAMYT Historical DataOctober 10, 2023 | investing.comLying in hospital… staring at the light"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.March 14, 2025 | Porter & Company (Ad)Beijing Sun-Novo Pharmaceutical Research Co. Ltd. AJuly 28, 2023 | wsj.com2022 for Chiesi: The Group’s international growth continuesApril 11, 2023 | finance.yahoo.comHigh Court of Justice of England and Wales Sanctions Scheme of ArrangementApril 3, 2023 | finance.yahoo.comAmryt Pharma Stock (NASDAQ:AMYT), DividendsMarch 17, 2023 | benzinga.comAMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023February 16, 2023 | finance.yahoo.comSee More Headlines AMYT Stock Analysis - Frequently Asked Questions How were Amryt Pharma's earnings last quarter? Amryt Pharma plc (NASDAQ:AMYT) posted its earnings results on Thursday, November, 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.66. The firm earned $49.33 million during the quarter. Amryt Pharma had a negative net margin of 8.19% and a positive trailing twelve-month return on equity of 1.70%. What other stocks do shareholders of Amryt Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amryt Pharma investors own include Alibaba Group (BABA), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Teladoc Health (TDOC), NIO (NIO), Tesla (TSLA). Company Calendar Last Earnings11/05/2020Today3/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMYT CIK1783010 Webwww.amrytpharma.com Phone353-1518-0200FaxN/AEmployees2,020Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1 million Net Margins-8.19% Pretax Margin-0.56% Return on Equity1.70% Return on Assets0.75% Debt Debt-to-Equity Ratio0.64 Current Ratio1.57 Quick Ratio0.94 Sales & Book Value Annual Sales$222.54 million Price / Sales4.22 Cash Flow$0.98 per share Price / Cash Flow14.98 Book Value$5.58 per share Price / Book2.63Miscellaneous Outstanding Shares63,960,000Free Float60,343,000Market Cap$940.21 million OptionableNot Optionable Beta0.84 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:AMYT) was last updated on 3/14/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredElon’s desperate gambleWarning: "DOGE Collapse" Imminent After months of cost-cutting, controversy, and media buzz, DOGE is on the...Altimetry | SponsoredTrump’s new tariffs could break China’s grip on manufacturingLooming trade wars have China scrambling… Over 90% of global corporate executives said they are shutting do...Weiss Ratings | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMore important than tariffs for your stocksMost people are obsessed with Trump's on-again, off-again tariffs. Yes, the economic uncertainly is playin...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amryt Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amryt Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.